Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS SOUTH AUSTRALIA INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:

PO Box 322,
Modbury,
South Australia 5092

Phone:
1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm
(phone)

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (PDF, 156KB)
Why become a member?

Ampligen to go back before the FDA as Chronic Fatigue Syndrome treatment

Monday 23 July 2012

 

From About.com's Adrienne Dellwo:

 

TabletsAmpligen To Go Back Before the FDA as Chronic Fatigue Syndrome Treatment

By Adrienne Dellwo, About.com Guide
July 16, 2012

Hemispherx Biopharma Inc. has announced that it will soon be putting Ampligen (rintatolimod), its prospective chronic fatigue syndrome (ME/CFS) drug, back before the U.S. FDA for approval.

The FDA rejected Ampligen in December 2009. In its complete response letter to Hemispherx, the agency outlined several steps by which the company could once again present the drug for approval. A key step was to complete at least one more clinical study including 300 or more patients.

Last March, Hemispherx instead published new data analysis from a previous trial showing that some, among other things, that participants taking Ampligen made improvements in exercise tolerance, which is one of the major problems for people with ME/CFS.

That analysis lead to a meeting between the company and the FDA on whether this new information would be sufficient to resubmit the drug under the original New Drug Application.

The company now says it will resubmit Ampligen before the end of September and the FDA will put it on a six-month review cycle. That means we should have a decision by the end of March.

Currently, no drugs are FDA approved for treating ME/CFS.

Ampligen is an immune-system modulator that's been in development for decades but has yet to be approved for any use.

NEWSLETTER | FORUM | BIO | TWITTER | FACEBOOK

 

The above, with comments, originally appeared here.

 


 

blog comments powered by Disqus
Previous Previous Page